Anti-angiogenic therapies have been developed based on the evidence that SA occurs upon VEGF secretion by hypoxic tumour cells; specific drugs have thus been designed to block VEGF signalling, but the occurrence of all these mechanisms alternative to SA greatly complicates the treatment of certain tumours33. Here, VEGFA is linked to neoplasm.